Test Price
2,800 AED✅ Home Collection Available
WFS1 Gene Deafness Autosomal Dominant Type 6 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee & Patient Safeguards
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM).
- Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by a DHA-licensed genetic counsellor.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The WFS1 NGS test is the gold-standard molecular diagnostic for autosomal dominant non-syndromic hearing loss DFNA6. It enables precise identification of pathogenic variants in the WFS1 gene with unmatched speed and clinical confidence. Next Generation Sequencing (NGS) with bioinformatic confirmation ensures full gene coverage including copy-number variant (CNV) analysis, delivering a definitive molecular diagnosis for patients and their families.
| Feature | Our Test (WFS1 NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Full gene coverage + CNV analysis | Selected exons only; may miss copy-number variants |
| Methodology | Next Generation Sequencing (NGS) with bioinformatic confirmation | Sanger sequencing, limited throughput |
| Turnaround Time | 3–4 weeks (comprehensive report) | 6–8 weeks (sequential exon walking) |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“A confirmed pathogenic variant in WFS1 provides the molecular explanation for DFNA6 hearing loss. However, audiometric testing and detailed family pedigree analysis remain indispensable for comprehensive patient management. We integrate the genetic result with pure-tone thresholds and counsel families about the slowly progressive nature of this condition. This test empowers the ENT specialist to schedule appropriate surveillance and early intervention — it is never a substitute for clinical vigilance when new symptoms emerge.”
Pre-Test Advisory
All individuals undergoing WFS1 genetic testing must receive pre-test genetic counselling from a qualified practitioner. A three-generation pedigree chart documenting all family members with hearing loss is required prior to sample submission. Results are reviewed by a board-certified clinical molecular geneticist and conveyed during a structured post-test tele-consultation.
Exclusion Criteria & Emergency Red Flags
- This test is not intended for acute, rapidly progressive hearing loss with onset under 72 hours — seek immediate ENT evaluation.
- Individuals under 18 must be accompanied by a legal guardian and undergo mandatory pre-test genetic counselling as per UAE paediatric guidelines.
- Do not use this test as a stand-alone tool to rule out syndromic deafness; a full clinical genetics assessment is always required.
- If sudden vertigo, tinnitus, or neurological symptoms accompany hearing loss, proceed directly to the nearest hospital emergency department.
Patient FAQ & Clinical Guidance
1. What does the WFS1 genetic test for deafness type 6 detect?
The test sequences all coding regions and intron-exon boundaries of the WFS1 gene to identify pathogenic single-nucleotide variants and copy-number alterations responsible for autosomal dominant non-syndromic hearing loss DFNA6. This provides a definitive molecular diagnosis for patients and enables informed family counselling.
2. How long does it take to receive results and who interprets them?
A comprehensive clinical report is generated within 3–4 weeks. The report is reviewed by a board-certified clinical molecular geneticist and then explained during a post-test tele-consultation with your referring ENT specialist or genetic counsellor.
3. Does this genetic test replace routine audiological checks?
No. The WFS1 genetic test complements, but never replaces, conventional audiometry and tinnitus assessment. It identifies the underlying genetic cause, while hearing tests monitor functional progression over time. Both are essential for optimal patient management.
4. Can home collection be arranged for this genetic test?
Yes. Since the required specimen is peripheral whole blood (or extracted DNA or FTA card blood spot), our VIP Mobile Phlebotomy and Temperature-Controlled Cold-Chain Home Collection service is available daily from 8 AM to 11 PM across Dubai and the Northern Emirates.
UAE Regulatory & Data Privacy Adherence
All testing and data handling at DNA Labs UAE strictly comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory is ISO 9001:2015 accredited (Cert: INT/EGQ/2509DA/3139) and holds DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | WFS1 Gene Deafness Autosomal Dominant Type 6 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (peripheral), extracted DNA, or FTA card blood spot |
| Methodology Used | Next Generation Sequencing (NGS) with bioinformatic CNV confirmation |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians